Post on 23-Feb-2016
description
transcript
Pharmaceuticals and Global Health
Inequalities and Innovation in the 21st Century
• Levels of funding• Nature of funding
• Product development partnerships• Innovative developing countries• What has been delivered?
• High risk R&D, long development / short political timelines
• Targeted funding to match R&D needs
• Diversification of funding
Improved sustainabilityin global health R&D
Enabling health impact in developing countries
Global trends in neglected disease R&D investment
2New business models for global health R&D
3Challenges and solutions for the future
1What has been invested in neglected disease R&D?
$2.5-3.3 billion per year in neglected disease R&D between 2007 and 2011
1What has been invested in neglected disease R&D?
1Which diseases are funded?
HIV/AIDS, 1117, 34%
Malaria, 596, 18%
Tuberculosis, 584, 18%
Dengue, 249, 8%
Diarrhoeal diseases, 169,
5%
Kinetoplastids, 142, 4%
Bacterial Pneu-monia & Menin-
gitis, 107, 3%
Helminths, 90, 3%Salmonella, 48, 1%
Trachoma, 10, 0%Leprosy, 8, 0%
Buruli ulcer, 6, 0%Rheumatic fever, 1, 0%
Platform technologies, 19, 1%
Core funding, 101, 3%Unspecified, 71, 2%
Neglected disease R&D funding by disease, FY2011 (US$m)
2nd tier/semi-commercial
Top tier diseases
3rd tier/diseases
1Who is investing in neglected disease R&D?
Public sector (HICs and multilaterals);
1877; 62%
Public (LMICs); 72; 2%
Private sector (MNCs); 469; 15%
Private sector (SMEs); 56; 2%
Philanthropic; 571; 19%
Neglected disease R&D funding by sector FY2011 (US$m)
1Top funders: Average annual funding 2007-2011
1. US NIH $1,159m 2. Bill & Melinda Gates Foundation $506m
3. Pharmaceutical industry $407m 4. European Commission: Research Directorate-General $113m
5. US Agency for International Development (USAID) $83m
6. US Department of Defense (DOD) $80m
7 We l l c o m e Tr u s t $ 7 2 m 8 . U K D e p a r t m e n t f o r I n t e r n a ti o n a l D e v e l o p m e n t ( D F I D ) $ 6 9 m
2How have developing countries benefitted?
2New business models for neglected disease R&D
Product Development PartnershipsInvolved in 40% of new products for global health R&D in last decade
Innovative Developing CountriesIncreasing government investment in domestic biotech innovation
MAJOR PHARMACEUTICAL INNOVATIONS
1.MENAFRIVAC2.XPERT MTB/RIF
3.COARTEM
2How have developing countries benefitted?
MenAfriVac. 56m vaccinated since 2011
Predicted to prevent 437,000 cases in next decade
Pharmaceutical Innovation
2How have developing countries benefitted?
Coartem Dispersible Over 171m delivered to 30+ malaria endemic countries
At costs as low as $0.38 per course of treatment.
Xpert MTB/RIF. Expected to triple diagnosis of drug resistant TB.
India alone, predicted to avert 100,000 deaths/year
Coartem. Since 2001, 400+ mil treatments provided on non-profit basis by Novartis.
Estimated 1mil lives saved.
360 products in development234 in preclinical, 289 in early clinical, 42 phase III trials
THERE ARE PROMISING CANDIDATES FOR HIV/AIDS, MALARIA, TUBERCULOSIS AND DENGUE
2New business models for neglected disease R&D
3Challenges and solutions for the future Currently growing pipeline may face untimely funding cuts
R&D pipelines need reliable long-term funding
Financial pressures mean smarter funding needed: Outcome driven and flexible Aligned with product and portfolio developments Coordinated Targeted to deliver the highest health impact
3Challenges and solutions for the future
Investment in neglected disease = R&D
Improved sustainabilityin global health R&D
Enabling health impact in
developing countries
+
Collaboration & partnerships
Building Capacity in Developing Countries
Quality Research
++ +
Targeted and flexible funding
Thank you Lindsey Wu Senior Analyst, Policy Cures lwu@policycures.org